Clinical Trials
12
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Sellas Life Sciences Group
- Registration Number
- NCT05593185
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies
- Conditions
- Hematologic Malignancies
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 160
- Registration Number
- NCT04588922
- Locations
- 🇺🇸
O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸Clinical Research Alliance, Inc., Lake Success, New York, United States
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Other: MontanideOther: Observation
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 127
- Registration Number
- NCT04229979
- Locations
- 🇺🇸
O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸UCLA Medical Hematology and Oncology, Los Angeles, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Whittier, California, United States
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
- Conditions
- Acute Myelogenous LeukemiaOvarian CancerColorectal CancerTriple-negative Breast CancerSmall-cell Lung Cancer
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 26
- Registration Number
- NCT03761914
- Locations
- 🇺🇸
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Innovative Clinical Research Institute (ICRI), Whittier, California, United States
🇺🇸Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 22
- Registration Number
- NCT01827137
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Prev
- 1
- 2
- Next
News
SELLAS Life Sciences Reports Promising Preclinical and Phase 2 Data for CDK9 Inhibitor SLS009 Across Multiple Hematologic Malignancies
SELLAS Life Sciences will present preclinical data showing SLS009 significantly prolonged survival in T-cell prolymphocytic leukemia models, with monotherapy achieving 7.4 weeks survival versus 4.4 weeks for venetoclax alone.
SELLAS Life Sciences Announces R&D Day to Showcase Phase 3 AML Trial Results and CDK9 Inhibitor Program
SELLAS Life Sciences will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders discussing acute myeloid leukemia treatment advances and unmet medical needs.
Schrödinger Discontinues Blood Cancer Drug SGR-2921 After Two Patient Deaths in Phase I Trial
Schrödinger has terminated development of its CDC7 inhibitor SGR-2921 after two patient deaths in a Phase I trial for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
SELLAS Life Sciences Receives Positive IDMC Recommendation to Continue Phase 3 REGAL Trial of Galinpepimut-S in AML
The Independent Data Monitoring Committee completed a pre-specified analysis of SELLAS' Phase 3 REGAL trial and recommended continuing the study without modification, finding no safety concerns.
Tambiciclib-Zanubrutinib Combo Shows 67% Response Rate in Relapsed/Refractory DLBCL Trial
Phase 2a trial demonstrates promising 67% overall response rate for tambiciclib plus zanubrutinib combination in relapsed/refractory DLBCL patients, including one complete response.
SELLAS Life Sciences Eyes Key Milestones for AML Therapies in 2025
SELLAS Life Sciences anticipates a pivotal 2025 with key clinical milestones for its hematologic malignancy therapies, including data readouts and regulatory feedback.
SELLAS Life Sciences' GPS Shows Promise in Phase 3 AML Trial, IDMC Recommends Continuation
The Independent Data Monitoring Committee (IDMC) recommended continuing SELLAS Life Sciences' Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML).
SELLAS' SLS009 Shows Promise in Phase 2 AML Trial
• SELLAS Life Sciences reports that SLS009, a CDK9 inhibitor, shows promising results in a Phase 2 trial for relapsed/refractory AML. • Patients in the 30 mg BIW cohort experienced a median overall survival exceeding 7.7 months, compared to the historical expectation of 2.5 months. • The overall response rate in AML patients with myelodysplasia-related changes reached 56%, surpassing the target response rate of 33%. • SLS009, combined with venetoclax and azacitidine, continues to demonstrate a favorable safety profile with no new concerns identified.
SELLAS' SLS009 Shows Promise in ASXL1-Mutated Solid Cancers
SELLAS Life Sciences reports that SLS009, a CDK9 inhibitor, demonstrates high efficacy in preclinical models of solid cancers with ASXL1 mutations.
T-Cell Malignancy Pipeline Shows Promise with Novel Therapies and Approvals
The T-cell malignancies market is experiencing growth driven by increased incidence, treatment advancements, and strategic biopharma partnerships.